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INTRODUCTION 
Burning mouth syndrome (BMS) is a disabling complex disorder characterized by painful 
and burning sensation of the oral cavity without detectable oral changes. BMS is common among 
women of postmenopausal age. The etiology and treatment are still being investigated; there are 
no specific therapy guidelines for BMS.
1,2
  Many conditions are thought to be precipitating 
factors, such as, nutritional deficiencies, oral infections, xerostomia and peripheral neuropathies.  
BMS is described as a bilateral burning pain, tingling, or numbness in the oral mucosa.
3 
This 
paper evaluates two double-blinded randomized controlled trials and one double-blinded 
randomized crossover trial to compare the efficacy of topical clonazepam to clonazepam PO in 
the treatment of BMS.  
The life-time prevalence of BMS ranges from 3.7%-40% in the elderly population, and it 
affects primarily postmenopausal women, with a gender ratio of 7:1.  Although BMS is 
commonly seen by the dentist it is managed by multidisciplinary teams within the scope of the 
physician assistant’s (PA) practice. 3, 4 Since BMS is a rare chronic condition, the exact 
healthcare cost of BMS has not been specified; however, the cost of charges for diseases of the 
mouth, excluding dental care, were $25,233 in 2011.
4,5
 An exact number of healthcare visits for 
BMS has not specified; however, the number of hospital discharges for diseases of the mouth, 
excluding dental care, was 21, 646 in 2011, and the average length of stay was 3.9 days in 2011.
5 
The etiology of BMS is unknown; however, it is thought to be neuropathic, associated 
with changes in the peripheral nervous system or central impairment suggested by 
neurophysiological testing, biopsies and MRI.
2, 4
 There is no consensus among clinicians on the 
diagnostic criteria of BMS; therefore BMS is often underdiagnosed.
3
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Some therapeutic strategies commonly used to treat BMS begin with dietary guidelines 
that suggest avoidance of food that is known to increase burning sensations such as alcohol, 
spicy foods and acidic drinks.  Anticonvulsants, antidepressants, analgesics and cognitive 
behavioral therapy have also been used in the management of BMS. According to Ducasse et 
al.’s review article, the anticonvulsants clonazepam and α-lipoic acid and cognitive behavioral 
therapy were the only treatments found to be effective in relieving symptoms.
3
 Currently, no 
clinical guidelines exist for BMS; however, clonazepam is one of the interventions found to be 
effective in improving symptoms in patients with BMS.
3
 The aim is to investigate whether or not 
topical clonazepam is more effective than clonazepam PO in the treatment of BMS.  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not topical 
clonazepam is more effective than clonazepam PO in treatment of BMS. 
METHODS 
Numerous studies were considered during the selection process for this paper. Only two 
double-blind randomized controlled trials and one double-blind randomized crossover trial were 
utilized based on the importance of the criteria for population, interventions, comparisons, and 
data included for patient-oriented outcomes (POEMS). The population was limited to patients 
with BMS with the following interventions: topical clonazepam 0.5mg and 1mg and PO 
clonazepam 0.5mg. Comparisons were made between the treatment group, who received either 
0.5mg of topical or 0.5mg of PO clonazepam and the experimental group who received a 
visually matched placebo. All subjects in the randomized crossover trial received 1mg of topical 
clonazepam. The outcomes measured were the efficacy of topical clonazepam and PO 
clonazepam for the treatment of BMS analyzed by pain ratings or VAS. Patients rated the 
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sensation of burning pain in the mouth on a scale ranging between 0 and 10, with 0 indicating no 
pain and 10 indicating maximum possible pain. Pain relief was measured by using a VAS from 0 
(no pain) to 10 (maximum possible pain).  
A detailed search was performed through PubMed and Cochrane Library databases using 
the key words, “clonazepam” and “burning mouth syndrome.” All three articles that were 
selected were published in the English language. Articles were selected based on their relevance 
to my clinical question and if they included POEMS. Exclusion criteria according to the three 
articles used were patients without BMS, patients with organic conditions which could have been 
a causative factor of BMS, vitamin B-12 deficiency, asthma, hepatitis, jaundice, HIV, diabetes 
mellitus, narrow-angle glaucoma, sleep apnea syndrome, candida infections of oral mucosa and 
patients with neurological conditions, to name just a few. 
1, 2 
Inclusion criteria for all chosen 
articles were studies that were randomized, controlled double-blinded crossover design with the 
use of topical or PO clonazepam as an intervention for BMS. The studies chosen were reported 
in continuous data, analysis of variance (ANOVA) F-score and change in mean from baseline, 
Chi square, and P-value to demonstrate statistical significance. Table 1 organizes the 
demographics and characteristics of all three articles discussed in this paper.  
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Table 1- Demographics and Characteristics of Included Studies1, 2, 6  
 
Study Type Pts 
# 
Age (yrs) Inclusion 
Criteria  
Exclusion 
Criteria 
W/D Intervention 
Heckmann1 
(2012) 
Double-blind 
RCT 
20 Experimental 
group 
65 ± 12.4 
Placebo  
62.9 ± 8.7 
Idiopathic 
cases 
 
Patients with 
the following: 
DM, 
Hepatitis, 
Jaundice, 
Inflammation 
and  Liver 
malfunctions, 
HIV, Vitamin 
B-12 
Deficiency, 
Asthma, 
Narrow angle 
glaucoma, 
Sleep apnea 
syndrome  
0 PO 
clonazepam 
0.5mg once 
daily for 9 wks 
Gremeau-
Richard2 
(2010) 
Double-blind 
Randomized 
Crossover 
20 Age over 50 
years old 
Presence of 
an isolated 
complaint of 
chronic pain 
in the oral 
mucosa. 
Normal 
clinical 
examination 
 
Patients with 
organic 
conditions 
that was 
liable to be a 
causative 
factor, such 
as DM and 
anemia. 
Patients with 
neurological 
conditions 
and those 
who were 
unable to 
understand a 
pain scale 
0 Topical 
clonazepam 
1mg and 
lidocaine 
TID for 3wks 
Rodriguez 
de Rivera 
Campillo6 
(2010) 
Double-blind 
RCT 
66 Avg age 64.9 
years 
Patient with 
BMS 
Patients with 
disorders in 
the oral 
mucosa. 
0 Topical 
clonazepam 
0.5mg once 
daily for 6mo 
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OUTCOMES MEASURED 
The outcomes measured in all three articles were those of patient-oriented evidence via 
pain ratings or VAS. Patients rated the sensation of burning pain in the mouth on a scale ranging 
between 0 and 10. Pain relief was measured by using a VAS from 0 to 10. Heckmann et al. 
utilized pain ratings; subjects were given a bottle of either sixty-three capsules of 0.5mg of 
clonazepam (Rivotril) or placebo (lactose monohydrate) to take orally once a day for nine weeks. 
The patients received a medication list in the form of a nine week calendar on which they had to 
mark off the intake and note the date each day.
1
 In the Gremeau-Richard et al. study, subjects on 
the first visit were asked to use the VAS to score their pain intensity before injection of lidocaine 
or saline, then again fifteen minutes after the injection. Subjects also answered a questionnaire. 
On the second visit which took place one week later, subjects received injections and all subjects 
were prescribed 1mg of topical clonazepam (Rivotril). Subjects were instructed to suck half a 
tablet for three minutes without swallowing and then to expectorate saliva. This procedure had to 
be repeated three times a day after each meal for three weeks. The effects of clonazepam were 
evaluated by comparing the mean scores obtained before the study and after three weeks.
2   
Lastly, Rodriguez de Rivera Campillo et al.’s subjects were given a sealed envelope containing 
thirty-two tablets of 0.5mg of topical clonazepam and instructed to take a single tablet in the 
morning, at the first sign of discomfort. Subjects were instructed to dissolve the tablet in the 
mouth for three minutes and, similar to the Gremeau-Richard et al. study, were instructed not to 
swallow and to expectorate saliva. Patients were asked to note their symptoms and instructed not 
to exceed four tablets a day. Burning sensation was measured by VAS during visits held at day 
one, then one month later and then again at six months.
6
 
RESULTS 
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Two of the three selected articles are double-blind randomized controlled trials while the 
third article is a double-blind randomized crossover trial. In all three articles clonazepam was 
used as an intervention for the treatment of BMS. In Heckmann et al.’s randomized controlled 
trial, patients were recruited to be part of the study based on the inclusion criteria restricted to 
idiopathic cases and exclusion criteria, such as systemic and central nervous system disease and 
pregnancy. During the recruitment process, patients received an examination of their oral cavity 
blood was drawn to screen for liver and kidney function, electrolytes and immunological 
parameters. The Beck Depression Inventory (BDI), Mini-Mental State Examination (MMSE), 
and Zerssen Mood Scale were used to screen for cognitive impairment, mood and depression 
disorders. After the initial examination three patients were excluded, and twenty moved on to 
participate in the RCT.  Blinding and randomization were performed by an independent 
individual using RandList, a specialized software program. Ten subjects (two men and eight 
women) were in the placebo group and 10 subjects (five men and five women) were in the 
treatment group. The age range of the placebo group was 49-78years, with a mean age of 65.4 
years, and the ages for the treatment group ranged from 49-89years, with a mean age of 67.5 
years. With regard to age, the groups were not significantly different with a p-value of .67. The 
subjects were given a bottle containing 63 capsules of either 0.5mg of clonazepam (Rivotril) PO 
or placebo (lactose monohydrate). Patients were instructed to take one capsule on an empty 
stomach with approximately 200mL of water once a day. The therapy session lasted for 9 weeks, 
during which they had to check off the intake of their capsules and note the date to insure 
compliance. At the end of the therapy session, the BDI and Zerssen Mood Scale were performed 
to investigate any adverse effects of medications.
1
 A summary of results can be seen in Table 2. 
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Table 2.  Descriptive Statistics of  Pain Ratings as Reported by Heckmann et al.
1 
 
Groups # of 
patients 
Session 1 
(mean and 
SD) 
Session 2 
(beginning of 
drug intake) 
Session 3 Session 4 
(end of 
drug 
intake) 
Session 5 p- value 
Placebo N= 10 6.0 ± 2.2 5.0 ± 2.0 4.6 ± 2.0 4.6 ± 2.4 4.5 ± 1.8 p = .011 
 
0.5mg  
Clonazepam 
PO 
N= 10  7.4 ± 2.4 4.1 ± 3.0 3.8 ± 3.0 3.9 ± 2.9 4.5 ± 2.4 p < .001 
 
To analyze data an ANOVA F-score and p-value were used to evaluate the change in mean from 
baseline. With a p < .001 the study demonstrated that taking 0.5mg of clonazepam PO over the 
span of 9 weeks has shown significant improvement in the symptom of pain in patients with 
BMS. The study shows that clonazepam was not only well tolerated by all participants but also 
effective. 
Rodriguez de Rivera Campillo et al.’s randomized controlled trial assessed the efficacy of 
0.5mg of topical clonazepam in the treatment of BMS. Sixty-six patients, 64 of whom were 
women, reported oral burning in the absence of apparent pathology. Patients with disease of the 
oral mucosa and those receiving treatment for BMS were excluded. Subjects taking anxiolytics 
or antidepressives were not rejected because of the high prevalence of BMS among patients with 
psychiatric disorders.
 6   
 A table of random numbers was used to ensure randomization of 
participants. Patients recorded their burning sensation using a VAS from 0 to 10. Six of the 
following variables were recorded for each patient: age, sex, duration of disease, location of 
burning sensation, drug consumption and systemic disease.
6  
 Two groups, each containing 33 
patients, were formed and received a sealed envelope containing 32 tablets of either 0.5mg of 
topical clonazepam or placebo (lactose tablet). Patients were advised to take a single tablet in the 
morning at the first sign of discomfort; if symptoms improved but then reappeared they were 
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allowed to take another tablet. They were instructed, however, not to exceed four tablets a day, 
making a total dose of 2 mg of topical clonazepam. Patients were instructed to dissolve tablets in 
the mouth for three minutes and then to expectorate the saliva. Patients were also asked to note 
their burning sensation. Patients returned after 1 week to assess adverse effects, if any. Then, 
patients were scheduled to return after 1 month and 6 months to monitor for adverse effects and 
measure VAS from 0 to 10. A summary of results can be seen in Tables 3 and 4.  
Table 3. Statistical Data of the VAS Values of Patients Reported by Rodriguez de Rivera Campillo et al. 
6 
 
 #  
Pts 
1
st
  day 1
st
 month 6
th
 month # Anxiolytic 
usage 
#Antidepressant 
usage 
# 
Psychological 
disease 
Topical 
Clonazepam 
33 7.69  ± 1.53 2.84 ± 1.69 3.03 ± 1.35 24 15 21 
Placebo 33 7.57 ± 1.58 4.24 ± 1.19 4.42 ± 0.96 25 18 20 
 
Table 4. Characteristic of Pain and Average Number of Tablets Taken by Patients Reported by  
Rodriguez de Rivera Campillo et al.
6 
 
 # Burning sensation 1
st
 month avg  # of tablets  6
th
 month avg # of tablets 
Topical clonazepam 33 70 62 
Placebo 33 95 84 
 
To analyze data, chi-square and p-value of the VAS scores were evaluated. Rodriguez de Rivera 
Campillo et al. demonstrated that on the  first day the differences between the groups were not 
statistically significant; however, after 1 month, 0.5 mg of topical clonazepam had a decrease in 
VAS scores with a p<.005, whereas the decrease in the placebo group was not statistically 
significant. Although a number of participants consumed anxiolytics and antidepressants and had 
psychological diseases, according to my interpretation of the data reported by Rodriguez de 
Rivera Campillo et al. was not significant enough to skew results.  The study also shows that the 
average number of tablets consumed was fewer than the number consumed by the placebo group, 
although not significant in those patients taking clonazepam.  The study reported that after one 
month, 23 of 33 subjects taking clonazepam showed more than a 50% reduction in symptoms 
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and five subjects were cured, compared to only 4 of 33 subjects from placebo group showing 
improvement. After six months 23 of 33 subjects taking clonazepam improved (p <.05), 
compared to only 2 of 33 subjects from the placebo group.
6 
          
The Gremeau-Richard et al. crossover trial evaluated the efficacy of the use of 1mg of 
topical clonazepam in 20 subjects who had previously received either lidocaine or saline 
injections. This trial was performed to assess the mechanism of the burning pain in these 
subjects, thus creating two subgroups, a “peripheral” and a “central” group. The peripheral group 
had pain relief while the central group had no relief of pain after lidocaine injections; however, 
the focus of this paper is to evaluate the intervention of topical clonazepam.  Inclusion criteria 
consisted of the presence of an isolated complaint of chronic oral pain, a normal examination, 
and pain present for at least 4 months. Patients with an organic condition and those who could 
not understand the VAS were excluded. Randomization was performed by the Clinical 
Investigation Centre (CIC) of Clemont-Ferrand University hospital pharmacy. On the first visit 
subjects completed a questionnaire and VAS scores on pain intensity before and after injections 
of lidocaine or saline. The questionnaire consisted of questions such as the following: Was the 
pain increased or decrease or same? Was there anesthesia or numbness of the tongue? On which 
side did the sensation change? During the second visit one week later, participants received 
another injection of either lidocaine or saline and completed the VAS before and after. After this 
visit all 20 subjects were given 1 mg of topical clonazepam (Rivotril) to take three times a day 
after each meal for 3 weeks. Patients were advised to suck half a tablet for 3 minutes and 
expectorate saliva.  During the third and last visit, 3 weeks later, patients were asked to score 
their pain intensity using VAS. A summary of results can be seen in Table 5. 
2
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Table 5. VAS Scores Before and After 3 Weeks of Topical Clonazepam Gremeau-Richard et al
2
   
    
 Baseline (before 
injections of 
lidocaine) (n=10) 
Baseline (before 
injections of 
saline) (n= 10) 
After 21 days of  
treatment with1 mg of 
topical clonazepam 
(n=20) 
p- value after 
clonazepam 
ΔVAS scores 5.6  ± 2.8 5.0 ± 2.4 2.1 ± 2.6  p = .002 
 
An ANOVA F-score and p-value were used to evaluate the VAS scores presented by Gremeau-
Richard et al. The study demonstrated that the treatment of topical clonazepam was very 
effective. Seven patients reported a pain intensity decrease of 2-8/10 on the VAS; six patients 
reported a decreased VAS score of 1-2/10, four patients experienced no pain relief and only three 
patients worsened. Thus, of 20 subjects, 13 subjects showed improvement.  Overall, all three 
studies reviewed in this paper showed a significant decrease in symptoms of BMS.  A summary 
of results from all three studies can be seen in Table 6. 
2 
Table  6. Summary of p- values Reported by Heckmann et al.
1
 Gremeau-Richard et al. 
2 
Rodriguez de Rivera Campillo et al.
6
 
 Route of clonazepam Data measured p -values 
Heckmann et al.
1
 
 
Oral (PO)  9 wks p<.001 
Gremeau-Richard et al. 
2
 
 
Topical 3wks p = .002 
Rodriguez de Rivera Campillo et al.
6
 Topical 1 mo and 6 mo p < .005,   p<.05 
 
DISCUSSION 
 All three articles showed that clonazepam, whether topical or PO, is safe, well tolerated, 
and significantly improves symptoms of BMS. A limitation that is apparent with all three 
articles, however, is the assessment of the use of clonazepam in the long-term management of 
BMS, because of the short duration of the trials, with the longest being 6 months reported by 
Rodriguez de Rivera Campillo et al.
  
According to Gremeau-Richard et al. one factor that may 
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affect outcome is the pathophysiology of BMS; there may be a peripheral and/or central 
mechanism that plays a role in a patient’s symptoms and response to treatment, specifically 
clonazepam. In Rodriguez de Rivera Campillo et al.’s study,   62% of subjects had psychological 
problems; the patients who were not suffering from psychological problems had a greater 
proportion of cures. Also, in this study some patients experienced sleepiness as an adverse effect. 
In the future, studies can be done to explore the pathophysiology of BMS, which can lead to 
better long-term management and clinical guidelines.  
CONCLUSION 
These studies have confirmed that clonazepam whether topical or PO is effective in the 
treatment of BMS. In analyzing the results from the three articles, it is evident that topical 
clonazepam is not more effective than clonazepam PO in the treatment of BMS.   
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